Intensity modulated radiation therapy vs 3D conformal radiotherapy in the radical treatment prostate cancer: Analysis of acute and late toxicity

Slavica Marić ,
Slavica Marić
Ljiljana Tadić-Latinović ,
Ljiljana Tadić-Latinović
Branislava Jakovljević ,
Branislava Jakovljević
Milan Žigić ,
Milan Žigić
Pavle Banović Orcid logo ,
Pavle Banović
Aleksandar Kostovski ,
Aleksandar Kostovski
Goran Kolarević
Goran Kolarević

Published: 01.12.2017.

Biochemistry

Volume 34, Issue 3 (2018)

pp. 1626-1633;

https://doi.org/10.5937/matmed1802626m

Abstract

Implementation of IMRT offers possibility to escalate radiation therapy dose without increased acute and late toxicity. The aim of this study is to compare acute and late genitourinary and gastrointestinal toxicity in patients treated with IMRT and 3DCRT technique. This study included 35 patients in study group A treated with IMRT technique, and 35 patients in study group B treated with 3DCRT technique. Patients were selected and referred to radical radiotherapy treatment prostate cancer. Acute genitourinary and gastrointestinal toxicity was evaluated during radiotherapy treatment according to recommendation of RTOG group. Late gastrointestinal and genitourinary toxicity was evaluated during regular control exams after radical radiotherapy treatment for six months. Based on the results χ2 test there was no statistical significant difference (p>0,05) between study group A i B in terms of acute gastrointestinal and genitourinary despite escalated radiotherapy dose in study group B treated with IMRT technique. Based on the results χ2 test there was no statistical significant difference (p>0, 05) between study group A i B in terms of late gastrointestinal and genitourinary toxicity. Intensity modulated radiation therapy is optimal technique in the radical treatment prostate cancer. This technique allows clinical benefit compared with 3D conformal radiotherapy-escalation of radiotherapy dose without increased toxicity in patients treated with IMRT technique.

Keywords

References

1.
Jemal A, Center MM, DeSantis C, Ward EM. Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiology, Biomarkers & Prevention. 2010;19(8):1893–907.
2.
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine. 2009;360(13):1320–8.
3.
NCCN Guidelines Version 1.2018. Prostate cancerJanuar. 2018;
4.
Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management. Cancer. 91(12):2302–14.
5.
Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, et al. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer – a systematic review. Radiotherapy and Oncology. 2002;64(3):239–50.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners